Shares of Sam Chun Dang Pharm were strong in the after-market (After-Market, 3:40 p.m.–8 p.m.) on the 22nd on news that its biosimilar (biopharmaceutical copycat) for treating macular degeneration received domestic marketing approval.
Sam Chun Dang Pharm stock traded at 270,000 won on Nextrade at 4:27 p.m. on the 22nd. That is 5.05% (13,000 won) higher than the day's regular-session closing price of 257,000 won. Sam Chun Dang Pharm notched a double-digit gain in the regular session to set a new all-time high of 261,000 won, and the rally continued in the after-market.
According to the Ministry of Food and Drug Safety's Integrated Drug Information System, Sam Chun Dang Pharm's "Vizenfry" received marketing approval that day. Vizenfry is a biosimilar of "Eylea (EYLEA, active ingredient aflibercept)." After receiving marketing authorization from the European Medicines Agency (EMA) 4th, sales channels have now opened in Korea as well.
Global sales of the original drug Eylea last year reached $9.523 billion (about 13.2 trillion won).